New meetings planned on proposed reservoir
Mounds Lake Reservoir project organizer Rob Sparks told Delaware County commissioners that the meetings will be held in March and April in Yorktown, Daleville, Chesterfield and Anderson.
Mounds Lake Reservoir project organizer Rob Sparks told Delaware County commissioners that the meetings will be held in March and April in Yorktown, Daleville, Chesterfield and Anderson.
Indiana lawmakers made decisions on a number of bills Monday at the Statehouse, including legislation involving hunting and fishing, home health care, cardiac arrest and more.
State lawmakers on Wednesday weighed in on legislation involving mobile-phone snooping, education issues, abortion restrictions, sex trafficking, guns, abandoned houses, veteran injuries and several more topics. Here’s a rundown.
Indiana regulators would be barred from adopting environmental rules tougher than federal standards under a bill that's advancing in the General Assembly that has drawn criticism that it would hamper efforts to protect the state's environment and public health.
For-profit colleges, bruised by years of investigations and rule-making, may face additional financial pressure from a new wave of state probes by attorneys general and the U.S. Consumer Financial Protection Bureau.
Legislation to require Indiana food-stamp recipients buy only products deemed nutritious was expanded Monday to include all Hoosiers who participate in the program.
Riley Hospital for Children at Indiana University Health has signed up 200 area pediatricians to be part of its new physician network. The move is the first step in an effort to build a statewide network of doctors that would use the Riley brand.
A Texas-based education organization with approval to open two Indianapolis charter schools teaches creationism and Christian-based character virtues, according to an article by Slate.com. It has prompted an expedited review of the group’s curriculum by Indianapolis and state education officials.
The folks at Lumosity, the San Francisco company that tries to improve human brain cognition, must have cheered when they saw this study partly led by a researcher at the Indiana University School of Medicine. The study, published this month by the Journal of the American Geriatrics Society, found that seniors who underwent exercises meant to boost mental sharpness still showed benefits up to a decade later. The study involved 2,800 seniors living independently in Indianapolis and six other regions. Lumosity, which makes a smartphone app to exercise your brain, is one of numerous programs, both online and offline, that are meant to boost mental sharpness in older adults.
Over-the-counter medications for common colds and allergies, such as DayQuil, could become harder to obtain under an Indiana House bill introduced this month. According to the Associated Press, HB-1106, authored by Rep. Rebecca Kubacki, R-Syracuse, would make medication containing ephedrine and pseudoephedrine a schedule III drug, which means it couldn’t be purchased without a doctor’s visit and prescription. An existing law puts a limit on how much ephedrine and pseudoephedrine can be purchased in a day, month or year. But, Kubacki said she doesn’t think the law goes far enough. However, Dr. Richard Feldman, chairman of legislation for the Indiana Academy of Family Physicians, said the medical community prefers the existing legislation to Kubacki’s new bill. “We think it’s adequate; we don’t want any more restrictions,” Feldman said. He added, “The last thing that the doctors I talked to want is to be overrun with patient visits for an over-the-counter drug that should remain over-the-counter, rather than seeing patients who deserve their attention.”
WellPoint Inc.’s core operations turned out more profit than the company predicted, the Indianapolis-based health insurer disclosed in a Jan. 13 securities filing. WellPoint raised its 2013 profit forecast to $8.52 per share, up 12 cents from a previous forecast of $8.40 per share. The company has yet to close its books on 2013. It will reveal its actual 2013 financial results Jan. 29. The new forecast roughly matches what Wall Street analysts were expecting. A survey of 23 analysts by Thomson Reuters found an average 2013 profit forecast of $8.51 per share, even before the disclosure. Both WellPoint’s and analyst forecasts exclude a variety of special charges, such as investment gains, the early extinguishment of debt, a favorable tax ruling and a charge related to WellPoint’s sale of its 1-800-Contacts subsidiary. When those items are included, WellPoint’s 2013 profit would total $8.20 per share, according to Monday’s disclosure. In October, WellPoint predicted full-year profit would total $8.45 per share. But that was before the 54-cent-per-share charge for the 1-800-Contacts sale was announced.
In late December 2013, the Health Foundation of Greater Indianapolis gave $440,376 to three organizations that will help Hoosiers navigate the Obamacare health insurance exchange. A grant of $270,000 was awarded to Indiana 2-1-1, a call-in service for obtaining information about social assistance, to maintain detailed information about the exchange navigators and application counselors that have been approved by the government to help exchange customers. A sample conducted in May 2013 showed that 38 percent of callers to Indiana 2-1-1 have at least one person in the household without health insurance. The Indiana Primary Health Care Association will receive $70,376 to train 26 certified Navigators to provide continuing education to at least 126 state-certified Navigators in state-funded and federally qualified health centers. Because of the cost of the federal certification process, many state-funded health centers, especially in rural areas, have been unable to certify their enrollment staff. Also, $100,000 was granted to Eskenazi Health to extend its media and outreach campaign through the end of the first open enrollment period in March 2014. The campaign promotes Eskenazi Health’s toll-free Navigator Call Center (1-855-202-1053), which answers consumer questions and provides assistance in obtaining health insurance through the Obamacare exchanges.
Under Senate Bill 225, authored by Sen. Luke Kenley, R-Noblesville, private firms may be able to build, abolish, or repair state facilities – and also operate them.
Commentary on New Jersey Gov. Chris Christie’s current troubles, after aides snarled traffic to punish a mayor who didn’t endorse him, has focused on the impact on his presidential aspirations.
The Democratic-controlled Senate planned to give final congressional approval to the immense spending measure, possibly as early as Thursday. The Republican-run House passed the package Wednesday in a lopsided 359-67 vote.
Downtown Indianapolis was recently ranked No. 1 for livability among smaller cities by Livability.com—gratifying praise after $9.3 billion of reinvestment. Recent debates and plans, however, have raised a fundamental question: Whose downtown is this?
Eli Lilly and Co.’s success at moving an experimental migraine medicine forward by using outside companies and capital is good news for this reason: The fundamental business of Big Pharma drug development is in bad shape.
Positive results from a Phase 2 trial in patients convinced Indianapolis-based Eli Lilly and Co. to reacquire an experimental migraine medicine, which goes by the name LY2951742. Lilly aims to conduct a Phase 3 trial, the last stage of testing before it can submit the drug for market approval. The drug was licensed from Lilly in 2011 by Massachusetts-based Arteaus Therapeutics, a company formed at the same time by venture capital firms OrbiMed and Atlas Venture. Lilly did not disclose the financial terms of its deal with Arteaus. However, Lilly will record a fourth-quarter charge of $57.1 million to reflect the reacquisition costs and Lilly’s assumption of ongoing development expenses of the drug. The drug is one of nine experimental drugs Lilly has licensed to outside firms as a way to share the risk of research and development costs. Lilly calls the risk-sharing arrangement with venture capital firms its Capital Funds Portfolio. The migraine medicine is the first one Lilly has reacquired from a participating venture-backed company.
Eli Lilly and Co. needs new drugs to patch a larger-than-expected hole in its revenue. On Jan. 7, the Indianapolis-based drugmaker revised its 2014 revenue forecast. Instead of its longstanding prediction of $20 billion in revenue, Lilly now expects to bring in between $19.2 billion and $19.8 billion. Wall Street analysts expected $19.6 billion, according to 17 estimates compiled by Bloomberg News. Revenue is falling at Lilly after its U.S. patents on antidepressant Cymbalta expired in December. Cymbalta generated $4.99 billion in 2012, but analysts expect its sales to plummet to $1.43 billion this year, according to Bloomberg. Also in March, Lilly will lose patent protection on its osteoporosis drug Evista. Analysts expect Evista sales to drop to $498.6 million this year from nearly $1 billion annually before. Lilly expects its 2014 profit to range between $2.77 and $2.85 per share. Analysts anticipated $2.78.
WellPoint Inc. plans to unwind one of the deals Angela Braly made late in her troubled tenure as CEO of the Indianapolis-based health insurer. WellPoint agreed to sell online contact lens retailer 1-800-Contacts to Boston-based private equity firm Thomas H. Lee Partners LP. WellPoint will also sell Glasses.com, a subsidiary of 1-800-Contacts, to Milan-based Luxottica Group SpA. WellPoint’s new CEO, Joe Swedish, said he wants to focus on its core insurance business. “As we prepare for the coming changes to the health-care system, we are focused on our core growth opportunities across both our commercial and government business segments,” Swedish said in the statement. “Proceeds from this transaction will support our continued capital deployment strategies.” WellPoint bought 1-800 Contacts from private equity firm Fenway Partners in June 2012 for about $900 million. The purchase added to investor anger against Braly. She left the company two months later.
The Indiana Family and Social Services Administration announced Friday it will add 3,400 people to the Healthy Indiana Plan, a health insurance program for low-income Hoosiers. That’s the number of Hoosiers who had been among the 50,000 on the program’s waiting list who reapplied and were deemed eligible. But state officials said they expect 20,000 Hoosiers to apply for HIP by the end of this year. The program, which had been running at about 40,000 participants, will have its enrollment capped this year at 45,000. Gov. Mike Pence is negotiating with the Obama administration to use HIP to expand coverage to all Hoosiers with incomes up to 138 percent of the federal poverty limit. For now, HIP participants cannot have incomes above the federal poverty limit, which is $11,490 per adult or $23,550 for a family of four.
Nationally, venture capital investments into life sciences firms totaled $4.9 billion during the first nine months of 2013, down 30 percent from the same period in 2008, according to data from Thomson Reuters and PricewaterhouseCoopers. In Indiana, life sciences firms raised $21 million during the first nine months of the year, far lower than any year since 2003.
An uncommonly ambitious gubernatorial want-list is paired with scores of items lawmakers are coveting during the 10-week gathering.
Many of us have just wished our friends and loved ones a healthy, happy and prosperous new year. In Indiana, those are going to be elusive goals.